Teresa S. Amaral

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 142 publications

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2026

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 19, 2026

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 19, 2026

Translating ctDNA into cutaneous melanoma care: An international expert survey.

Translating ctDNA into cutaneous melanoma care: An international expert survey.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 13, 2026

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].

Corrigendum to "Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028": [ESMO Open 10 (2025) 104295].

Journal: ESMO open

Published: January 03, 2026

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Insights into RAS-driven melanoma and its therapeutic implications.

Insights into RAS-driven melanoma and its therapeutic implications.

Journal: Cancer treatment reviews

Published: November 29, 2025

Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.

Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis.

Journal: Journal for immunotherapy of cancer

Published: November 07, 2025

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 31, 2025

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020.

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: October 24, 2025

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 03, 2025

Genetic susceptibility in early-onset melanoma: An observational Greek cohort study.

Genetic susceptibility in early-onset melanoma: An observational Greek cohort study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 29, 2025

Showing 1-12 of 142

Last Updated: 09/26/2026